Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Adenoviral Human p53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable, Locally Advanced Head and Neck Cancer - a Open-labeled Randomized Phase 2 Study

NCT02429037 is registered in ClinicalTrials.gov with Shenzhen SiBiono GeneTech Co.,Ltd as lead sponsor.

NCT NCT02429037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02429037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Adenoviral Human p53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable, Locally Advanced Head and Neck Cancer - a Open-labeled Randomized Phase 2 Study
Lead sponsor
Shenzhen SiBiono GeneTech Co.,Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2015
Completion date
December 31, 2018
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced head and neck cancer